Lee Sang Bong, Jeon Hui-Jeon, Hyun Hoon, Jeon Yong Hyun
SimVista Inc., 194-25, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si 28161, Republic of Korea.
Department of Biomedical Sciences, Chonnam National University Medical School, 264, Hwasun 58128, Republic of Korea.
Cancers (Basel). 2025 Jul 7;17(13):2266. doi: 10.3390/cancers17132266.
To overcome the limitations of conventional CRC (colorectal cancer) mouse models in replicating metastasis and enabling efficient therapeutic evaluation, we developed a novel implantation method using tissue adhesive to establish reproducible orthotopic and metastatic tumors. Conventional models using injection or suturing techniques often suffer from technical complexity, inconsistent tumor establishment, and limited metastatic reliability. We developed and validated a novel orthotopic and metastatic CRC model utilizing tissue adhesive for tumor transplantation. Uniform tumor fragments derived from bioluminescent HCT116/Luc xenografts were affixed to the cecum of nude mice. Tumor growth and metastasis were monitored through bioluminescence imaging and confirmed by the results of histological analysis of metastatic lesions. The model's utility for therapeutic testing was evaluated using MK801, an NMDA receptor antagonist. The biological-based model demonstrated rapid and reproducible tumor implantation (<5 min), consistent primary tumor growth, and robust metastasis to the liver and lungs. The biological-based approach achieved 80% tumor engraftment (4/5), with consistent metastasis to the liver and lungs in all mice, compared with lower and variable metastasis rates in injection (0%, 0/5) and suturing (20%, 1/5) methods. MK801 treatment significantly suppressed both primary tumor growth and metastasis, validating the model's suitability for preclinical drug evaluation. By enabling rapid, reproducible, and spontaneous formation of metastatic lesions using a minimally invasive tissue adhesive technique, our model represents a significant methodological advancement that supports high-throughput therapeutic screening and bridges the gap between experimental modeling and clinical relevance in colorectal cancer research.
为了克服传统结直肠癌(CRC)小鼠模型在复制转移和进行有效治疗评估方面的局限性,我们开发了一种使用组织粘合剂的新型植入方法,以建立可重复的原位和转移性肿瘤。使用注射或缝合技术的传统模型常常存在技术复杂、肿瘤建立不一致以及转移可靠性有限的问题。我们开发并验证了一种利用组织粘合剂进行肿瘤移植的新型原位和转移性CRC模型。将源自生物发光HCT116/Luc异种移植瘤的均匀肿瘤片段固定在裸鼠的盲肠上。通过生物发光成像监测肿瘤生长和转移,并通过转移性病变的组织学分析结果进行确认。使用NMDA受体拮抗剂MK801评估该模型在治疗测试中的效用。这种基于生物学的模型显示出快速且可重复的肿瘤植入(<5分钟)、一致的原发性肿瘤生长以及向肝脏和肺部的强劲转移。与注射(0%,0/5)和缝合(20%,1/5)方法中较低且可变的转移率相比,这种基于生物学的方法实现了80%的肿瘤植入(4/5),所有小鼠均出现向肝脏和肺部的一致转移。MK801治疗显著抑制了原发性肿瘤生长和转移,验证了该模型适用于临床前药物评估。通过使用微创组织粘合剂技术实现转移性病变的快速、可重复和自发形成,我们的模型代表了一项重大的方法学进步,支持高通量治疗筛选,并弥合了结直肠癌研究中实验建模与临床相关性之间的差距。